Why A Surge In Drug Pricing Litigation Is Unlikely

Law360 (July 24, 2020, 6:14 PM EDT) -- High drug prices have long been a rallying cry in the news media and political discourse. The intense public discussion of prices for COVID-19 vaccines or treatments — before the U.S. Food and Drug Administration has even approved any vaccine or drug for the disease — perfectly captures the inherent tension in setting drug prices. 

In fact, just last week President Trump signed four executive orders targeting drug pricing and called for pharmaceutical manufacturers to come to the table with alternative proposals within 30 days.[1]

Pharmaceutical companies are pouring resources into accelerated research and development to try to meet an urgent...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!